Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1632 1647
This examiner grants 40% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18289049 | ASSESSING AND TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18691666 | CELLULAR THERAPY TO SUPPRESS IMMUNE RESPONSE | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18518384 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | Non-Final OA | Juno Therapeutics, Inc. |
| 18562108 | METHODS FOR THE TREATMENT OF OSTEOARTHRITIS | Non-Final OA | Novartis AG |
| 18292247 | COMPOSITIONS AND METHODS FOR ENHANCING CAR T CELL EFFICACY THROUGH THE ENGINEERED SECRETION OF C. PERFRINGENS NEURAMINIDASE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18296711 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | Non-Final OA | SANOFI |
| 18326605 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES IN ELDERLY PATIENTS | Final Rejection | Hoffmann-La Roche Inc. |
| 18563037 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPY | Non-Final OA | Celgene Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy